158 related articles for article (PubMed ID: 37854325)
1. Diagnostic value of aldo‑keto reductase family 1 member B10 in human nasopharyngeal carcinoma.
Lu J; Kang T; Zhang Z
Mol Clin Oncol; 2023 Nov; 19(5):89. PubMed ID: 37854325
[TBL] [Abstract][Full Text] [Related]
2. Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Guo Y; Luo W; Hu Z; Li J; Li X; Cao H; Li J; Wen B; Zhang J; Cheng H; Guo W; Tan T; Luo D
Cell Biosci; 2016; 6():18. PubMed ID: 26949513
[TBL] [Abstract][Full Text] [Related]
3. AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma.
Liu X; Hu Z; Qu J; Li J; Gong K; Wang L; Jiang J; Li X; He R; Duan L; Luo W; Xia C; Luo D
Int J Biol Sci; 2021; 17(3):756-767. PubMed ID: 33767586
[TBL] [Abstract][Full Text] [Related]
4. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
5. Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis.
Park A; Choi SJ; Park S; Kim SM; Lee HE; Joo M; Kim KK; Kim D; Chung DH; Im JB; Jung J; Shin SK; Oh BC; Choi C; Nam S; Lee DH
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563425
[TBL] [Abstract][Full Text] [Related]
6. Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma.
Wang Z; Kong L; Zhang R; Yang X; Cao Z; Xu T; Zhang H; Dou Y
J Hepatocell Carcinoma; 2024; 11():131-143. PubMed ID: 38250307
[TBL] [Abstract][Full Text] [Related]
7. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Han C; Gao L; Bai H; Dou X
Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
[TBL] [Abstract][Full Text] [Related]
8. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.
Orita N; Kawaguchi K; Honda M; Shimode T; Hayakawa N; Terashima T; Komura T; Nishikawa M; Horii R; Nio K; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S; Kagaya T; Yamashita T
Biochem Biophys Res Commun; 2023 Sep; 674():133-139. PubMed ID: 37419034
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
11. Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Chen D; Shen Z; Cheng X; Wang Q; Zhou J; Ren F; Sun Y; Wang H; Huang R
Bioengineered; 2021 Dec; 12(1):1964-1975. PubMed ID: 34027794
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression.
Robinson K; Cao Z; Delfino K; Cao D; Rao K
J Int Med Res; 2023 Jun; 51(6):3000605231179317. PubMed ID: 37389562
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Liu R; Zheng S; Yang CY; Yu Y; Peng S; Ge Q; Lin Q; Li Q; Shi W; Shao Y
Medicine (Baltimore); 2021 Apr; 100(14):e25454. PubMed ID: 33832153
[TBL] [Abstract][Full Text] [Related]
14. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
15. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
16. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
17. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Yoshitake H; Takahashi M; Ishikawa H; Nojima M; Iwanari H; Watanabe A; Aburatani H; Yoshida K; Ishi K; Takamori K; Ogawa H; Hamakubo T; Kodama T; Araki Y
Int J Gynecol Cancer; 2007; 17(6):1300-6. PubMed ID: 17425679
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
20. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Shi J; Chen L; Chen Y; Lu Y; Chen X; Yang Z
J Cancer; 2019; 10(20):4892-4901. PubMed ID: 31598161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
